Abstract: A new corona virus sparked the pandemic of the novel COVID-19 virus, which has spread around the world. SARS-CoV-2 (severe acute respiratory syndrome corona virus is a corona virus that causes severe acute respiratory syndrome. It is the sixth known corona virus to infect people; four of these coronaviruses are 229E, NL63, OC43, and HKU1 which spreads with mild symptoms. SARS-CoV, MERS-CoV, and SARS-CoV-2, on the other hand, elicit severe symptoms and have a 40% fatality rate.N501Y, D614G, K417N, and T478K are among the changes that may assist the virus resist neutralizing antibodies produced by vaccination or past infection. At this point, it’s difficult to say how transmissible it is. In response to the continuous emergence of new SARS-CoV-2 variations, the FDA updated the EUAs of some authorized molecular, antigen, and serology tests on September 23, 2021, to establish additional Conditions of Authorization. These conditions necessitate, among other things, that test developers update their authorized labeling and assess the influence of SARS-CoV-2 viral changes on their test’s performance. The Delta form then spread quickly until mid-December, accounting for nearly 99 percent of COVID-19 cases and causing a massive surge in hospitalizations. Sub Delta Variant (AY.4.2), which represents for 8% of corona virus cases sequenced, has two distinct mutations in the spike: Y145H and A222V. The Delta plus Variant (AY.1), on the other hand, has an extra mutation on the spike protein termed K417N. It’s been suggested that this modification decreases the binding affinity of ACE2 by a little amount. On November 30, 2021, the United States identified the omicron version of SARS-CoV-2, B.1.1.529, as a Variant of Concern. The omicron variety has a lot more mutations than other SARS-CoV-2 variants, especially in the S-gene, which codes for the virus’s spike protein. The FDA is collaborating with government partners and test producers to assess the effects of the omicron variant on SARS-CoV-2 diagnostic tests, as well as to create a vaccine and medication to combat the current mutant corona virus.